How effective are monoclonal antibodies for the treatment of pediatric atopic dermatitis (AD)?

Updated: Apr 26, 2021
  • Author: Robert A Schwartz, MD, MPH; Chief Editor: Dirk M Elston, MD  more...
  • Print

Dupilumab, a monoclonal antibody targeting the α-subunit of the IL-4 receptor to produce inhibition of both the IL-4 and IL-13 pathways, is of value in moderate-to-severe atopic dermatitis. [63, 68]  Lebrikizumab, an investigational anti–IL-13 monoclonal antibody, may prove of value in children as an add-on to topical corticosteroid therapy. [71]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!